SCHEMBL3534816

SCHEMBL3534816

Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C(=O)N5CCN(C(C)C)CC5)cnc(N)c34)cc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.69
AURKB Q96GD4 13/20 0.69
KIT P10721 8/20 0.63
AURKA O14965 8/20 0.63
CSF1R P07333 8/20 0.63
FLT1 P17948 8/20 0.63
FLT3 P36888 8/20 0.63
NEK2 P51955 7/20 0.63
LCK P06239 7/20 0.63
FYN P06241 7/20 0.63
MET P08581 7/20 0.63
FGFR1 P11362 7/20 0.63
BLK P51451 7/20 0.63
STK3 Q13188 7/20 0.63
ROCK1 Q13464 7/20 0.63
NTRK2 Q16620 7/20 0.63
PLK4 O00444 6/20 0.63
ROCK2 O75116 6/20 0.63
INSR P06213 6/20 0.63
LYN P07948 6/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528845 0.91 KDR (0.72) KDRAURKBKITAURKACSF1R
SCHEMBL3527697 0.91 KDR (0.72) KDRAURKBKITAURKACSF1R
SCHEMBL3528322 0.89 KDR (0.69) KDRAURKBKITAURKACSF1R
SCHEMBL3524653 0.89 KDR (0.69) KDRAURKBKITAURKACSF1R
SCHEMBL3528015 0.89 KDR (0.68) KDRAURKBKITAURKACSF1R
SCHEMBL3531798 0.87 KDR (0.70) KDRAURKBKITAURKACSF1R
SCHEMBL3525442 0.86 KDR (0.65) KDRAURKBKITAURKACSF1R
SCHEMBL3528491 0.83 KDR (0.83) KDRAURKBKITAURKACSF1R
SCHEMBL3530647 0.83 KDR (0.83) KDRAURKBKITAURKACSF1R
SCHEMBL3526143 0.82 KDR (0.80) KDRAURKBKITAURKACSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885KIT 188/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885KIT 188/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885KIT 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.